Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Historical Holders from Q2 2017 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
MRSN on Nasdaq
Shares outstanding
4,992,318
Price per share
$7.76
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
55,398
Total reported value
$410,881
% of total 13F portfolios
0%
Share change
-77,141,852
Value change
-$31,452,219
Avg sell value change
-0%
Number of holders
5
Price from insider filings
$9.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nextech Crossover I GP S.a r.l. 10% $3,620,174 12,067,246 Nextech Crossover I GP S.a. r.l. 20 Dec 2024
VANGUARD GROUP INC 6.7% $2,513,330 8,377,767 The Vanguard Group 31 Mar 2025
BlackRock, Inc. 3% -53% $1,354,275 -$1,642,317 3,761,876 -55% BlackRock, Inc. 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% -68% $1,072,298 -$2,005,040 3,574,325 -65% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Schonfeld Strategic Advisors LLC 5.5% +19% $2,122,973 -$41,906,118 273,579 -95% Schonfeld Strategic Advisors LLC 30 Sep 2025
As of 30 Sep 2025, Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) has 5 institutional shareholders filing 13F forms. They hold 55,398 shares of 4,992,318 outstanding shares (1.1%) .

Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 55,398 $410,881 -$31,452,219 $7.76 5
2025 Q2 77,200,692 $22,849,022 -$3,437,347 $0.2960 80
2025 Q1 87,949,584 $30,265,069 -$35,777,227 $0.3442 109
2024 Q4 104,300,678 $149,147,565 -$24,958,582 $1.43 129
2024 Q3 116,077,343 $219,445,253 +$3,272,082 $1.89 115
2024 Q2 114,206,357 $229,554,439 -$23,968,090 $2.01 121
2024 Q1 117,492,700 $526,342,059 +$29,071,617 $4.48 124
2023 Q4 46,033 $106,797 +$5,573 $2.32 1
2023 Q3 113,736,983 $144,444,348 -$76,688,572 $1.27 126
2023 Q2 112,399,497 $369,792,909 +$12,914,278 $3.29 145
2023 Q1 106,417,299 $436,359,202 +$18,980,399 $4.11 154
2022 Q4 101,142,467 $592,695,970 +$39,121,650 $5.86 149
2022 Q3 85,121,162 $575,431,568 +$49,778,849 $6.76 144
2022 Q2 87,770,975 $405,499,031 +$41,984,975 $4.62 118
2022 Q1 80,785,582 $322,375,381 +$33,199,358 $3.99 125
2021 Q4 60,516,526 $376,419,924 -$4,565,593 $6.22 113
2021 Q3 66,673,984 $628,735,103 -$40,893,817 $9.43 107
2021 Q2 70,515,120 $957,028,788 -$10,361,127 $13.58 128
2021 Q1 67,300,338 $1,088,884,080 -$33,285,890 $16.18 128
2020 Q4 65,661,810 $1,747,251,515 +$31,226,645 $26.61 143
2020 Q3 66,930,327 $1,246,264,156 +$47,689,893 $18.62 129
2020 Q2 63,860,476 $1,494,292,389 +$669,054,013 $23.40 127
2020 Q1 40,113,728 $233,861,407 +$26,424,535 $5.83 81
2019 Q4 35,451,536 $203,134,553 -$6,013,694 $5.73 68
2019 Q3 35,661,134 $56,343,070 -$6,861,654 $1.58 69
2019 Q2 37,565,444 $152,161,717 +$5,949,799 $4.05 75
2019 Q1 36,928,875 $194,243,065 +$104,827,316 $5.26 64
2018 Q4 16,357,847 $66,738,155 -$9,125,682 $4.08 45
2018 Q3 19,816,887 $198,166,730 +$71,378 $10.00 45
2018 Q2 19,130,665 $341,672,448 +$7,920,216 $17.86 51
2018 Q1 18,728,332 $295,349,347 +$23,732,992 $15.77 56
2017 Q4 16,409,744 $269,579,465 -$3,736,848 $16.43 45
2017 Q3 16,648,048 $287,842,000 +$10,579,447 $17.29 40
2017 Q2 16,970,149 $236,408,000 +$236,407,446 $13.97 29